|
 
- 积分
- 414
- 威望
- 414
- 包包
- 645
|
本帖最后由 细胞海洋 于 2014-1-4 09:43 编辑
" P; e1 c9 i6 ?* U5 K
! t; p. u& \4 DMolecular therapies* x+ R) D! `/ {0 `3 R4 V
Dr. Zoltán Balajthy, Dr. János Aradi, Dr. Zoltán Balajthy, Dr. Éva Csősz, Dr. Beáta Scholtz, Dr. István Szatmári, Dr. József Tőzsér, Dr. Tamás Varga (2011)
0 ?* M9 ~/ f$ `8 R& H2 M0 {" i; v; Z* A- {7 |0 _
University of Debrecen
) h. H: a: o3 P. Y$ V; OCopyright © 2011 The project is funded by the European Union and co-financed by the European Social Fund., Manuscript completed: 17 November 2011
9 E, ^0 e4 ?8 [! S+ h7 W! c) K: |$ F2 C0 I. L; i3 ?9 c% b! R6 B
: o+ o( m- y& y1 t1 Q4 v4 r
. y( A, D, l9 I" V( lIndex
* H! h& q- b2 a7 f" H8 @1. 1. Functional Genomics
2 u: _4 n1 n0 G& v1.1 Definitions. P0 C" v9 u+ Q2 D8 f, J
1.2 About diseases
7 R1 A+ e) Q- Q1.3 Approaches to understanding disease mechanisms4 U% b g" ]# `( H" R$ h% v
1.3.1 Gene expression is regulated in several basic ways+ E- I( Y# A8 O
1.3.2 Microarrays: functional genomics in cancer research5 x# D4 ^. g8 L8 g1 H
1.3.3 A Variety of Genetic Alterations Underlie Developmental Abnormalities and Disease4 K3 A& G, B8 M# f# J L3 p
1.3.4 Genomic microarrays0 e! G7 H5 J2 Z1 {0 {1 _3 V3 n* S
2. 2. Recombinant proteins. l. V& c, j) O: Y6 N8 c
2.1 Overview: Protein pharmaceuticals/ e% b, z, R I+ b9 O Y" ]
2.2 Cell-free systems: In vitro transcription and translation$ {4 H0 z, p. i% y [/ \
2.3 Recombinant protein expression in isolated cells (cell culture)
# c7 _1 `3 l7 {; W* b2.4 Non-prokaryotic expression systems
9 i* f+ L1 e5 a+ F2.4.1 Cloning in Pichia pastoris
o4 U9 [+ i4 ?" ]/ c) }2.4.2 Baculovirus mediated protein expression in insect cells
z! Y# @9 g7 m2.4.3 Mammalian expression systems
2 R* {8 r* M- _7 B" t2.5 Purification of recombinant proteins, q: y' {) _- c! {- D, B Y
3. 3. Gene Therapy: Vectors and Strategies.
3 [5 J; n3 U6 M# t5 E7 v3.1 Vectors for Gene Therapy* c- B2 e0 }9 ~% I0 {
3.2. Types of gene transfer, vectors for gene therapy
2 o& \3 d% N2 s) v) c# _7 }0 @1 y5 |3.3. General gene therapy strategies
1 O0 R/ u4 d: I8 C+ x- _2 G8 s, n3.4. Human gene therapy) E2 P+ y2 f/ C' T
4. 4. Protein replacement therapies.
: _ W' |! ~; m& y5. 5. Recombinant antibodies and the phage display technology
* ~* e3 M$ a! @$ ]5.1. Introduction8 L r8 B7 h6 [# |; {6 m! F
5.1.1. The structure of antibodies and their production in the body! `8 c' e! ?5 _% X' U) R
5.1.2. Antigen-antibody binding
& e# a1 Q3 o$ X& r: Z- H) {; U$ K5.2. The production of therapeutic antibodies
" b9 `7 \1 \3 L+ R/ H5 `5.2.1. The production of antibodies in hybridoma cells.% ~+ Y- Q3 i- w6 x1 X7 K
5.2.2. Humanized antibodies$ L: D- i+ t7 S' _
5.2.3. Production of human antibodies( j7 w0 k1 \/ `3 s+ n# t6 a
5.3. Generation of antibodies by phage display7 B- B, ~7 |7 ]
5.3.1. The phage display technology7 J/ Y7 t2 ^" y! n$ W6 D
5.3.2. Generation of phage libraries* `* n7 y2 p( X3 {* L) s# y+ Z
5.4. Administration of therapeutic antibodies
) Z! a- i# f$ S& O6. 6. Anti-cytokine Therapy (sepsis).' O. R# H- \& D
6.1. The consequences of developing inflammation
0 c: {- i" {) ~% Q n+ a* g% n6.2. Development of Inflammatory Response: Synthesis of Lipid Mediators* ?4 E. ~- `" q) _2 ]! |, C' ?
6.3. Role of the Liver in Maintenance of Homeostasis: Acute Phase Response( ^; a O2 P5 v: \- Z. ]
6.4. Time-Course of the Inflammatory Response During Sepsis
; d* w0 F- m) m6 j6 B; G7. 7. Animal models and transgenesis in biotechnology
8 S+ E8 n& r1 u& G! i4 k8. 8. Embryonic and adult stem cells in regenerative medicine I.4 Y' P1 @$ v# u( |0 _; y
8.1 Embryonic stem cells- z8 C1 T2 q1 N
8.2 Somatic cell reprogramming into pluripotent stem cells. q/ o( D3 U0 W5 g* ^- D
8.3 Adult stem cells* `+ r0 o$ G' E4 O
9. 9. Embryonic and adult stem cells in regenerative medicine II.
, \3 |2 C0 c) [* b! h: D9.1 Pluripotent stem cells for regenerative medicine
+ \( ^% }) d& y+ k9.2 Clinical application of stem cells
. B! }$ e% f) O1 I& o: S9.3 Stem cell therapy to cure various diseases5 R: [7 k5 B! n3 g- m
10. 10. Cell Cycle and Cancer Therapy, p53 I.
1 l* L0 R) v; {6 }2 V7 |4 `10.1 Cell Cycle1 Q1 a1 ^* O2 [7 \6 @8 w
10.2. Mitogenic Signaling in Eukaryotic Cell Controls the Rate of Cell Division0 Q5 H3 S" m6 l( U
10.3. Biochemical Events of Cell-cycle – in M Phase Q+ V1 O1 z6 C" O6 D
10.4. Protooncogenes' |) i. U6 k( x. i
10.5. ErbB/HER Receptors
/ ?4 O, O4 w- K8 Y) \& D. p/ u10.6. Therapeutic targets
" f* B6 j; k' C) i9 ~4 u$ q11. 11. Cell Cycle and Cancer Therapy, p53 II.
2 t% z8 y9 e( Q x( \/ L3 i$ X11.1. Tumor Suppressor Genes and p53* R! A9 Q" l4 X5 Z
11.2. Biochemical Pathways of Apoptosis and its Therapeutic Utilization
+ {2 P/ q& A: W+ v& E* M/ ]12. 12. Gene Silencing Technologies.
6 l2 X% S! f9 J3 C( g4 w ]0 e12.1 Introduction
- G0 }9 O1 S% F* V( H! A! a, ?/ w12.2 Action of antisense oligonucleotides
& _2 _( d5 n) X1 q12.3 Chemical modifications of gene silencing oligonucleotides; general considerations
$ n/ G+ F; `8 ?9 o f$ k3 ?+ U12.4 Inhibition of transcription by triple helix forming oligonucleotides% P- C5 A o0 p) p+ {# P* F0 m$ e
12.5 Gene silencing by ribozymes1 D6 d5 g1 x" e& j
12.6 Gene silencing with short RNA fragments7 E7 R; G$ R" w8 J; U: D
12.7 Important final note
( \3 x" j3 `# P1 d$ i# G( E) Y
, M/ J7 C* \. u- K+ t3 U* U* x[hide][/hide] |
附件: 你需要登录才可以下载或查看附件。没有帐号？注册
-
总评分: 威望 + 5
包包 + 20
查看全部评分
|
发表于 2014-1-3 16:18
